Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management: a United States perspective

Author： Schmier Jordana K. Covert David W. Robin Alan L.

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.23, Iss.11, 2007-11, pp. : 2867-2875

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Persistence with Prostaglandin Agonist Use with and without Adjunctive Therapy for Glaucoma Patients: A Canadian Population-Based Analysis

By Iskedjian Michael

The Patient: Patient-Centered Outcomes Research, Vol. 4, Iss. 2, 2011-06 ,pp. : 133-141

Adis International

Access to resources Recommend Favorite

First-year treatment patterns among new initiators of topical prostaglandin analogs

By Schmier Jordana K. Covert David W. Robin Alan L.

Current Medical Research and Opinion, Vol. 25, Iss. 4, 2009-04 ,pp. : 851-858

Informa Healthcare

Access to resources Recommend Favorite

First-year treatment costs among new initiators of topical prostaglandin analog identified from November 2007 through April 2008

By Schmier Jordana K. Covert David W. Robin Alan L.

Current Medical Research and Opinion, Vol. 26, Iss. 12, 2010-12 ,pp. : 2769-2777

Informa Healthcare

Access to resources Recommend Favorite

Blepharoptosis onset after topical prostaglandin therapy for glaucoma

CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Vol. 1442-6404, Iss. 7, 2015-09 ,pp. : 689-690

John Wiley & Sons Inc

Access to resources Recommend Favorite

Blepharoptosis onset after topical prostaglandin therapy for glaucoma

CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Vol. 43, Iss. 7, 2015-09 ,pp. : 689-690

John Wiley & Sons Inc

Access to resources Recommend Favorite